— Know what they know.
Not Investment Advice
Also trades as: SABSW (NASDAQ) · $vol 0M

SABS NASDAQ

SAB Biotherapeutics, Inc.
1W: -5.2% 1M: -9.2% 3M: -0.6% YTD: -8.5% 1Y: +35.3% 3Y: -59.4% 5Y: -96.5%
$3.45
+0.01 (+0.29%)
 
Weekly Expected Move ±5.4%
$3 $3 $4 $4 $4
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 30 · $33.0M mcap · 8M float · 11.36% daily turnover · Short 44% of daily vol
Smart Money Score
Moderate 50
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$33.0M
52W Range1.85-5.15
Volume240,357
Avg Volume899,298
Beta0.53
Dividend
Analyst Ratings
7 Buy 1 Hold 0 Sell
Consensus Buy
Company Info
CEOSamuel J. Reich
Employees86
SectorHealthcare
IndustryBiotechnology
IPO Date2021-02-09
Websitesab.bio
777 W 41st St.
Miami Beach, FL 33140
US
605 679 6980
About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Recent Insider Trades

NameTypeSharesPriceDate
Kropotova Alexandra F-InKind 988 2026-06-25
Kropotova Alexandra F-InKind 988 2026-03-24
Sullivan Eddie Joe A-Award 3,000,000 $4.45 2026-02-03
Reich Samuel J A-Award 4,800,000 $4.45 2026-02-03
Bausch Christoph Law A-Award 1,800,000 $4.45 2026-02-03

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms